NASDAQ:ALLO - Allogene Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$25.4537 +0.03 (+0.12 %)
(As of 12/18/2018 12:49 PM ET)
Previous Close$25.42
Today's Range$25.26 - $26.18
52-Week Range$21.67 - $35.55
Volume188,251 shs
Average Volume416,047 shs
Market Capitalization$3.19 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the research, development, and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, a CAR T cell product candidate targeting CD19, which is in clinical trials in patients with R/R B-cell precursor acute lymphoblastic leukemia; ALLO-501, an allogeneic anti-CD19 CAR T cell product candidate for the treatment of patients with R/R non-Hodgkin lymphoma; ALLO-715, an allogeneic CAR T cell product candidate for the treatment of patients with R/R multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepleting agent. It is also developing ALLO-819, an anti-Flt3 product candidate for the treatment of acute myeloid leukemia; CD70 for the treatment of renal cell cancer; and DLL3 for the treatment of small cell lung cancer. The company was founded in 2017 and is headquartered in South San Francisco, California.

Receive ALLO News and Ratings via Email

Sign-up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALLO
Previous Symbol
CUSIPN/A
Phone650-457-2700

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees78
Outstanding Shares121,480,000
Market Cap$3.19 billion
OptionableNot Optionable

Allogene Therapeutics (NASDAQ:ALLO) Frequently Asked Questions

What is Allogene Therapeutics' stock symbol?

Allogene Therapeutics trades on the NASDAQ under the ticker symbol "ALLO."

What price target have analysts set for ALLO?

4 brokers have issued 12 month target prices for Allogene Therapeutics' shares. Their predictions range from $29.00 to $41.00. On average, they expect Allogene Therapeutics' share price to reach $33.6667 in the next year. This suggests a possible upside of 31.5% from the stock's current price. View Analyst Price Targets for Allogene Therapeutics.

What is the consensus analysts' recommendation for Allogene Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Allogene Therapeutics.

Has Allogene Therapeutics been receiving favorable news coverage?

News headlines about ALLO stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Allogene Therapeutics earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 8.0 out of 10, indicating that recent news coverage is very likely to have an effect on the stock's share price in the near future.

Who are some of Allogene Therapeutics' key competitors?

Who are Allogene Therapeutics' key executives?

Allogene Therapeutics' management team includes the folowing people:
  • Mr. Joshua A. Kazam, Co-Founder & Director (Age 41)
  • Dr. Arie S. Belldegrun F.A.C.S., M.D., FACS, Co-Founder & Exec. Chairman (Age 69)
  • Dr. David D. Chang M.D., Ph.D., Co-Founder, Pres, CEO & Director (Age 58)
  • Dr. Eric Thomas Schmidt Ph.D., Chief Financial Officer (Age 50)
  • Dr. Alison Moore Ph.D., Chief Technical Officer (Age 51)

When did Allogene Therapeutics IPO?

(ALLO) raised $272 million in an IPO on Thursday, October 11th 2018. The company issued 16,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies acted as the underwriters for the IPO.

When does Allogene Therapeutics' lock-up period expire?

Allogene Therapeutics' lock-up period expires on Tuesday, April 9th. Allogene Therapeutics had issued 18,000,000 shares in its public offering on October 11th. The total size of the offering was $324,000,000 based on an initial share price of $18.00. After the end of Allogene Therapeutics' lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

How do I buy shares of Allogene Therapeutics?

Shares of ALLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Allogene Therapeutics' stock price today?

One share of ALLO stock can currently be purchased for approximately $25.60.

How big of a company is Allogene Therapeutics?

Allogene Therapeutics has a market capitalization of $3.19 billion. Allogene Therapeutics employs 78 workers across the globe.

What is Allogene Therapeutics' official website?

The official website for Allogene Therapeutics is http://www.allogene.com.

How can I contact Allogene Therapeutics?

Allogene Therapeutics' mailing address is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-457-2700 or via email at [email protected]


MarketBeat Community Rating for Allogene Therapeutics (NASDAQ ALLO)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  42 (Vote Outperform)
Underperform Votes:  49 (Vote Underperform)
Total Votes:  91
MarketBeat's community ratings are surveys of what our community members think about Allogene Therapeutics and other stocks. Vote "Outperform" if you believe ALLO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALLO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/18/2018 by MarketBeat.com Staff

Featured Article: What are earnings reports?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel